Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Jan
07
Today In Oncology
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer
Study Finds Patients With Colon Cancer and Obesity Receiving GLP-1 RAs Had Significantly Reduced Risk of Mortality
A Novel Paradigm in Acute Kidney Injury Congestive Nephropathy in RCC With IVC Thrombus
Physical Activity and Fatigue QOL in Nonmetastatic CRC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo